{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:58:37Z","timestamp":1768438717598,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015640","name":"Tongji Hospital","doi-asserted-by":"publisher","award":["81803387"],"award-info":[{"award-number":["81803387"]}],"id":[{"id":"10.13039\/501100015640","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China National Pharmaceutical Group Corporation (China)","award":["4100712"],"award-info":[{"award-number":["4100712"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Background: The incidence of invasive fungal disease (IFD) has increased significantly, and IFD is a major cause of mortality among those with hematological malignancies. As a novel second-generation triazole antifungal drug offering both efficacy and safety, isavuconazole (ISA) is recommended by various guidelines internationally for the first-line treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) infecting adults. Given that it was only approved in China at the end of 2021, there is currently a lack of statistical data regarding its usage in the Chinese population. The primary objective of this report is to describe early experiences with ISA for the treatment of IFD. Methods: This was a real-world, multicenter, observational case series study conducted in China. It included patients from three centers who received ISA treatment from January 2022 to April 2023. A retrospective assessment on patient characteristics, variables related to ISA administration, the treatment response of IFD to ISA, and potential adverse events attributed to ISA was conducted. Results: A total of 40 patients met the inclusion criteria. Among them, 12 (30%) were diagnosed with aspergillosis, 2 (5%) were diagnosed with candidiasis, 12 (30%) were diagnosed with mucormycosis, and 14 cases did not present mycological evidence. The predominant site of infection was the lungs (36), followed by the blood stream (8), sinuses (4), and respiratory tract (2). The overall response rate was 75% (30 patients), with male patients having a higher clinical response than female patients (24\/24 versus 6\/16, p = 0.000) and autologous stem cell transplant patients having a higher clinical response than allogeneic stem cell transplant patients (6\/6 versus 4\/10, p = 0.027). During the observation period, four patients experienced adverse effects associated with ISA, but none of them discontinued the treatment. Conclusions: Our findings suggest that ISA, a novel first-line treatment for IA and IM, is associated with a high clinical response rate, low incidence, and a low grade of adverse effects. Given the short time that ISA has been available in China, further research is needed to identify its efficacy and safety in the real world.<\/jats:p>","DOI":"10.3390\/microorganisms11092229","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T02:26:12Z","timestamp":1693794372000},"page":"2229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World, Multicenter Case Series of Patients Treated with Isavuconazole for Invasive Fungal Disease in China"],"prefix":"10.3390","volume":"11","author":[{"given":"Lisha","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"},{"name":"Department of Pharmacy, Huangjiahu Hospital, Hubei University of Traditional Chinese Medicine, Wuhan 430065, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shougang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, General Hospital of Central Theater Command of Chinese People\u2019s Liberation Army, Wuhan 430070, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixi","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hubei General Hospital, Renmin Hospital of Wuhan University, Wuhan 430060, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infection Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-1767","authenticated-orcid":false,"given":"Yan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"ref_1","unstructured":"Chinese Association Hematologists, and Chinese Invasive Fungal Infection Working Group (2020). The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision). Zhonghua Nei Ke Za Zhi, 59, 754\u2013763."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1038\/s41467-022-32249-5","article-title":"The importance of antimicrobial resistance in medical mycology","volume":"13","author":"Gow","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/cid\/cix130","article-title":"Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis","volume":"64","author":"Lamoth","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","article-title":"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: A multicenter, prospective, observational study in China","volume":"36","author":"Sun","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eimc.2018.03.018","article-title":"Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC\/REIPI","volume":"37","author":"Castro","year":"2019","journal-title":"Enfermedades Infecc. Y Microbiol. Clin. Engl. Ed."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","unstructured":"Anti-infection Group of Hematology Branch of Chinese Medical Association, Hematology Hospital, Chinese Academy of Medical Sciences, and Department of Hematology, Nanfang Hospital, Southern Medical University (2023). Consensus recommendations for the clinical application of isavuconazole. Lin Chuang Xue Ye Xue Za Zhi, 36, 295\u2013302."},{"key":"ref_10","unstructured":"Medical Mycology Society of Chinese Medicine and Education Association, and Chinese Society of Hematology, Chinese Medical Association (2023). Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi, 44, 92\u201397."},{"key":"ref_11","unstructured":"Medical Mycology Society of Chinese Medicine and Education Association, and Chinese Mucormycosis Expert Consensus Group (2023). Expert consensus on diagnosis and management of mucormycosis in China. Zhonghua Nei Ke Za Zhi, 62, 597\u2013605."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: A new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Kontoyiannis","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e01783-19","DOI":"10.1128\/AAC.01783-19","article-title":"A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/myc.12777","article-title":"Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species","volume":"61","author":"Marty","year":"2018","journal-title":"Mycoses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dagher, H., Hachem, R., Chaftari, A.M., Jiang, Y., Ali, S., Deeba, R., Shah, S., and Raad, I. (2022). Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant. J. Fungi, 8.","DOI":"10.3390\/jof8010074"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/HS9.0000000000000320","article-title":"Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study","volume":"3","author":"Cattaneo","year":"2019","journal-title":"HemaSphere"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e0178421","DOI":"10.1128\/spectrum.01784-21","article-title":"Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)","volume":"10","author":"Monforte","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/TP.0000000000004312","article-title":"Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice","volume":"107","author":"Bodro","year":"2023","journal-title":"Transplantation"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zurl, C., Waller, M., Schwameis, F., Muhr, T., Bauer, N., Zollner-Schwetz, I., Valentin, T., Meinitzer, A., Ullrich, E., and Wunsch, S. (2020). Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations. J. Fungi, 6.","DOI":"10.3390\/jof6020090"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-021-00607-4","article-title":"Mucormycosis in Mainland China: A Systematic Review of Case Reports","volume":"187","author":"Wei","year":"2022","journal-title":"Mycopathologia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e13469","DOI":"10.1111\/tid.13469","article-title":"Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience","volume":"23","author":"Vu","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e14045","DOI":"10.1111\/tid.14045","article-title":"Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole","volume":"25","author":"Scott","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/myc.12910","article-title":"Real-world use-Isavuconazole at a large academic medical center","volume":"62","author":"Hassouna","year":"2019","journal-title":"Mycoses"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/myc.12213","article-title":"Our 2014 approach to breakthrough invasive fungal infections","volume":"57","author":"Maschmeyer","year":"2014","journal-title":"Mycoses"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: A 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole As Successful Salvage Therapy for Mucormycosis in Pediatric Patients","volume":"39","author":"Bilavsky","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40265-014-0227-3","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: Clinical implications","volume":"74","author":"Autmizguine","year":"2014","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.1038\/s41598-023-31788-1","article-title":"Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies","volume":"13","author":"Hamed","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"myad033","DOI":"10.1093\/mmy\/myad033","article-title":"Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study","volume":"61","author":"Pieragostini","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e12751","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol\/Norethindrone in Healthy Adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: A multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e02629","DOI":"10.1128\/AAC.02629-18","article-title":"No Dose Adjustment for Isavuconazole Based on Age or Sex","volume":"63","author":"Desai","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/9\/2229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:45:58Z","timestamp":1760129158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/9\/2229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["microorganisms11092229"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11092229","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}